The tweet was deleted by the author.
But we saved everything 🙂.
Moderna announced that the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating its investigational mRNA-1469 vaccine for Bundibugyo ebolavirus disease. At the same time, Moderna stock is up 3.4% on the day at $57.06.
The announcement, made by Moderna itself, states that a Phase 1 clinical trial is underway in Canada for mRNA-1469, an investigational vaccine candidate against Bundibugyo ebolavirus disease. The detail that matters is that the first participants have started receiving the vaccine after Health Canada authorized the study. This milestone in the clinical development process is a typical step in biotechnology research and does not signal a change in the company's commercial activities or regulatory status. Contextually, analyst sentiment toward the stock remains mixed, with a median price target below current levels and the most recent rating from Morgan Stanley at equal-weight.
View post on X Loading...
There is no clear link between the news and the latest price action in shares of Moderna, as the timing of the post and the session move cannot be directly connected. Instead, trading is being shaped by technical considerations, with the daily chart showing the price below both the MA-20 and MA-50 but still holding above the MA-200, which points to a divided structure. Notably, a significant gap up at the open stands out against an overall bearish backdrop, while the Stoch RSI nearing oversold territory hints that the recent pullback may be approaching a limit.
To determine if the move is gaining traction, traders should watch for sustained action above resistance. The session’s most prominent signal was the opening gap from $55.14 to $56.75, setting the tone for early trading interest. From here, the probabilities for the coming trading week show a 33% chance of upside and a 67% chance of downside, with an expected range between $54.28 and $59.83. A close above $58.55 would confirm buyers are following through, while a drop below $52.77 would indicate the move is being faded. On the weekly chart, the broader outlook remains constructive.
Earlier, analysts noted that investors were focused on the commercialization of Moderna's pipeline beyond COVID-19, with the stock exhibiting heightened volatility following quarterly results. The initiation of the mRNA-1469 Phase 1 trial adds an additional clinical catalyst to monitor, but with technical signals still mixed, a sustained move above or below the $58.55 and $52.77 levels, respectively, will be critical for direction in coming sessions.